Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,410 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Sörensen H, Zeidler H, Sieper J. Braun J, et al. Among authors: schneider m. Ann Rheum Dis. 2008 Mar;67(3):340-5. doi: 10.1136/ard.2007.075879. Epub 2007 Oct 29. Ann Rheum Dis. 2008. PMID: 17967831 Free article. Clinical Trial.
Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.
Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Golder W, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Reddig J, Sieper J. Braun J, et al. Among authors: schneider m. Arthritis Rheum. 2003 Aug;48(8):2224-33. doi: 10.1002/art.11104. Arthritis Rheum. 2003. PMID: 12905476 Free article. Clinical Trial.
Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Sieper J. Braun J, et al. Among authors: schneider m. Rheumatology (Oxford). 2005 May;44(5):670-6. doi: 10.1093/rheumatology/keh584. Epub 2005 Mar 9. Rheumatology (Oxford). 2005. PMID: 15757965 Clinical Trial.
Treatment continuation in patients receiving biological agents or conventional DMARD therapy.
Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, von Hinueber U, Gromnica-Ihle E, Wassenberg S, Antoni C, Herzer P, Kekow J, Schneider M, Rau R. Zink A, et al. Among authors: schneider m. Ann Rheum Dis. 2005 Sep;64(9):1274-9. doi: 10.1136/ard.2004.031476. Epub 2005 Feb 11. Ann Rheum Dis. 2005. PMID: 15708884 Free PMC article.
Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?
Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, Listing J. Strangfeld A, et al. Among authors: schneider m. Ann Rheum Dis. 2011 Nov;70(11):1914-20. doi: 10.1136/ard.2011.151043. Epub 2011 Jul 25. Ann Rheum Dis. 2011. PMID: 21791449 Free PMC article.
Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction.
Baraliakos X, Heldmann F, van den Bosch F, Burmester G, Gaston H, van der Horst-Bruinsma IE, Krause A, Schmidt R, Schneider M, Sieper J, Andermann B, van Tubergen A, Witt M, Braun J. Baraliakos X, et al. Among authors: schneider m. RMD Open. 2016 Jul 19;2(2):e000272. doi: 10.1136/rmdopen-2016-000272. eCollection 2016. RMD Open. 2016. PMID: 27493791 Free PMC article.
7,410 results